Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Hsiehchen

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
The Oncologist|March 11, 2022
Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy BenefitSharlene Dong, Heba Zakaria, David Hsiehchen
Cancer Research Communications|October 20, 2025
Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and OutcomesPrashanth Gowda, Saiabhiroop R Govindu, David Hsiehchen
Cancer Research Communications|September 29, 2023
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular CarcinomaMir Lim, Maishara Muquith, Bernadette Miramontes, et al.
Cancer Biology & Therapy|August 16, 2021
Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assayDavid Hsiehchen, Magdalena Espinoza, David E Gerber, et al.
Oncology|July 26, 2018
Ibrutinib Use Complicated by Progressive Multifocal LeukoencephalopathyDavid Hsiehchen, Reuben Arasaratnam, Karuna Raj, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumabSaiabhiroop Govindu, Prashanth Gowda, Maishara Muquith, et al.
Gastrointestinal Endoscopy|September 19, 2019
Trends and clinical features of intentional and accidental adult foreign body ingestions in the United States, 2000 to 2017Antony Hsieh, David Hsiehchen, Sabrina Layne, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groupsDavid Hsiehchen, Magdalena Espinoza, Cristina Valero, et al.
JAMA Network Open|September 19, 2019
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint InhibitorsDavid Hsiehchen, Mary K Watters, Rong Lu, et al.
Nature Communications|July 1, 2025
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trialDavid Hsiehchen, Radhika Kainthla, Heather Kline, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
The Oncologist|March 11, 2022
Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy BenefitSharlene Dong, Heba Zakaria, David Hsiehchen
Cancer Research Communications|October 20, 2025
Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and OutcomesPrashanth Gowda, Saiabhiroop R Govindu, David Hsiehchen
Cancer Research Communications|September 29, 2023
Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular CarcinomaMir Lim, Maishara Muquith, Bernadette Miramontes, et al.
Cancer Biology & Therapy|August 16, 2021
Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assayDavid Hsiehchen, Magdalena Espinoza, David E Gerber, et al.
Oncology|July 26, 2018
Ibrutinib Use Complicated by Progressive Multifocal LeukoencephalopathyDavid Hsiehchen, Reuben Arasaratnam, Karuna Raj, et al.
Journal for Immunotherapy of Cancer|January 16, 2026
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumabSaiabhiroop Govindu, Prashanth Gowda, Maishara Muquith, et al.
Gastrointestinal Endoscopy|September 19, 2019
Trends and clinical features of intentional and accidental adult foreign body ingestions in the United States, 2000 to 2017Antony Hsieh, David Hsiehchen, Sabrina Layne, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groupsDavid Hsiehchen, Magdalena Espinoza, Cristina Valero, et al.
JAMA Network Open|September 19, 2019
Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint InhibitorsDavid Hsiehchen, Mary K Watters, Rong Lu, et al.
Nature Communications|July 1, 2025
Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trialDavid Hsiehchen, Radhika Kainthla, Heather Kline, et al.
Pageof 7